Champix
PreclinicalSmall molecule
Jeil Pharmaceutical Co., Ltd.Champix is one of 22 small molecule programs targeting Smoking Cessation. It is currently in Preclinical.
1
Indications
5
Total Trials
0
Active Trials
21
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
29 competitors in Smoking Cessation
#DrugCompanyPhaseTrials
1Nicorette
PfizerApproved
Chantix
PPrism Pharmaceuticals
Approved
Wellbutrin
GGlaxo Dba Glaxosmithkline
Approved
Lunesta
Akero TherapeuticsApproved
Viagra
VViatris Specialty LLC
Approved
Nicotine Free Cigarettes
PfizerPhase 3
Belsomra
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Inderal
WWyeth-Lederle Vaccines
Approved
Nicotine Lozenge
FFertin Pharma A/S
Phase 3
Mounjaro
Eli LillyPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Clinical Trial1 trial
Smoking Cessation1 trial
Adult1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Champix. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details